Novo Nordisk inventory jumps on raised FY22 outlook as Ozempic drives Q3 gross sales

Novo Nordisk (NVO) (OTCPK:NONOF) shares rose pre-market on Wednesday after the corporate raised its FY22 outlook following its Q3 outcomes.

The diabetes-focused drugmaker noticed Q3 GAAP EPS develop +20% Y/Y to DKK6.34, whereas web revenue enhance +19% to DKK14.41B.

The Denmark-based firm’s Q3 web gross sales grew +28% (+15% at fixed change charges -CER) Y/Y DKK45.57BB.

“We’re very happy with the gross sales development within the first 9 months of 2022 which has enabled us to boost the outlook for the total 12 months. The expansion is pushed by growing demand for GLP-1-based diabetes remedies, particularly Ozempic,” stated President and CEO Lars Fruergaard Jørgensen.

Diabetes care section gross sales grew 26% Y/Y to DKK 36.13B in Q3.

Complete Gross sales from GLP-1 therapies section elevated +62% Y/Y to DKK22.37B.

Blockbuster medication Ozempic (semaglutide) gross sales rose (+63% at CER) Y/Y to ~DKK16.39B, Rybelsus income elevated (+101% at CER) Y/Y to DKK3.01B.

Nonetheless, Victoza noticed a decline in gross sales of (-26% at CER) Y/Y to DKK2.97B.

Complete Gross sales from insulin portfolio declined -7% Y/Y (-15percentat CER) to DKK12.96B.

Complete Weight problems care section gross sales elevated 81% Y/Y to DKK4.33B. Weight reduction drug Saxenda income elevated 69% to ~DKK3.17B, whereas new weight reduction drug Wegovy, which can be a model of semaglutide, generated gross sales of DKK1.16B +123% Y/Y.

Uncommon illness section gross sales grew +13% Y/Y to DKK5.116B.

Different metrics: Working revenue elevated +32% Y/Y to ~DKK20.18B. Working margin was 44.3%, in comparison with 42.8% in Q3 2021.

Novo Nordisk (NVO) free money circulation elevated +1% Y/Y to ~DKK19.77B.

Inventory buyback program: As of Oct 31. Novo purchased again ~21.53M B shares price DKK16.60B as a part of the general share repurchase program of as much as DKK24B.

Outlook:

Novo Nordisk (NVO) stated it now expects FY22 gross sales development to be 14% to 17% (at CER) in comparison with prior forecast throughout Q2 outcomes 12% to 16%. Gross sales development (as reported) is predicted to be ~10 proportion factors larger than at CER, in comparison with prior steering of ~9 proportion factors larger than at CER.

The corporate expects working revenue development to be between 13% to 16% at CER, beforehand 11% to fifteen%. Working revenue as reported) is predicted to be ~15 proportion factors larger than at CER, in comparison with prior steering of 14 proportion factors larger than at CER.

NVO +4.74% to $111.47 premarket Nov. 2